Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

(2009) Jan C. Buckner et al.   INVESTIGATIONAL NEW DRUGS

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

(2008) Stephen M. Ansell et al.   CANCER

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

(2008) G. Folprecht et al.   CLINICAL CANCER RESEARCH

A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH